Aktuellt
SENASTE
Redeye provides an initial take on Sedana Medical’s Q2 results, and we will return with a more in-depth take on the report. We are glad to see other direct market sales growing handsomely and argue that as 2025 comes closer, the potential inflexion points it entails are highly interesting for the share.
LÄS MER
